Contineum Therapeutics, Inc. Class A Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Total operating expenses were $33,923,000.
Profit Margin
| 2023 | 50M | 22.72M | 45.44% |
|---|
CTNM Income Statement (2023 – 2023)
| 2023 | |
|---|---|
Revenue | |
Revenue | 50M |
Cost of revenue | 0 |
Gross profit | 50M |
Operating exp. | |
Research and development | 27.60M |
Selling and marketing | 0 |
Total operating expenses | 33.92M |
Operating income | 16.07M |
Other income (expenses), net | 7.09M |
Income before tax | 23.17M |
Income tax expense | 450K |
Net income | 22.72M |
Earnings per share | |
Basic EPS | 1.36 |
Diluted EPS | 1.28 |